Literatur
-
1
Dose M.
Priorität für Atypika? Aktuelle Studien rücken einiges zurecht.
Psychiat Prax.
2007;
34
46-49
-
2
Fritze J, Aldenhoff J, Bergmann F, Maier W, Möller H-J. für die Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) und die Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) .
CATIE: Die Auswahl von Antipsychotika bei Schizophrenie.
Psychoneuro.
2005;
31
523-525
-
3
Lieberman J A, Stroup T S, McEvoy J P, Swartz M S, Rosenheck R A, Perkins D O, Keefe R SE, Davis S M, Davis C E, Lebowitz B D, Severe J, Hsiao J K.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia.
New England Journal of Medicine.
2005;
353
1209-1223
-
4
Wieck A, Haddad P.
Hyperprolactinaemia caused by antipsychotic drugs. This common side effect needs more attention.
BMJ.
2002;
324
250-252
-
5
Kleinberg D L, Davis J M, de Coster R, Van Baelen B, Brecher M.
Prolactin levels and adverse events in patients treated with risperidone.
J Clin Psychopharmacol.
1999;
19
57-61
-
6
McEvoy J P, Meyer J M, Goff D C, Nasrallah H A, Davis S M, Sullivan L, Meltzer H Y, Hsiao J, Stroup T S, Lieberman J A.
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Schizophr Res.
2005;
80
19-32
-
7
Baptista T.
Body weight gain induced by antipsychotic drugs: Mechanisms and management.
Acta Psychiatr Scand.
1999;
100
3-16
-
8
Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, Lippmann S.
Body Weight Changes Associated With Psychopharmacology.
Psychiatr Serv.
2002;
53
842-847
-
9
Nasrallah H A.
Focus on Lower Risk of Tardive Dyskinesia with Atypical Antipsychotics.
Ann Clin Psychiatry.
2006;
18
57-62
-
10 Tamminga C A, Woerner M G. Clinical course and cellular pathology of tardive dyskinesia. Neuropsychopharmacology: The Fifth Generation of Progress (Meltzer H, ed). 2002: 1831-1841
-
11
Ballesteros J, González-Pinto A, Bulbena A.
Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies.
J Clin Psychopharmacol.
2000;
20
188-194
-
12
Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S. et al .
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
JAMA.
2003;
290
2693-2702
-
13
Beasley C M, Dellva M A, Tamura R N, Morgenstern H, Glazer W M, Ferguson K. et al .
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Br J Psychiatry.
1999;
174
23-30
-
14
Csernansky J G, Mahmoud R, Brenner R. Risperidone-USA-79 Study Group .
A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.
N Engl J Med.
2002;
346
16-22
-
15
Correll C U, Leucht S, Kane J M.
Lower risk for tardive dyskinesias associated with second-generation antipsychotics: a systematic review of 1-year studies.
Am J Psychiatry.
2004;
161
414-425
-
16
Mishara A L, Goldberg T E.
A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
Biol Psychiatry.
2004;
55
1013-1022
-
17
Thornton A E.
The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review.
J Psychopharmacology.
2006;
20
335-346
-
18
Hugenholtz G W, Heerdink E R, Stolker J J, Meijer W E, Egberts A C, Nolen W A.
Haloperidol Dose When Used as Active Comparator in Randomized Controlled Trials With Atypical Antipsychotics in Schizophrenia: Comparison With Officially Recommended Doses.
J Clin Psychiatry.
2006;
67
897-903
-
19
Geddes J, Freemantle N, Harrison P, Bebbington P. for the National Schizophrenia Guideline Development Group .
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis.
BMJ.
2000;
321
1371-1376
-
20
Taylor D.
Low dose typical antipsychotics - a brief evaluation.
Psychiatric Bulletin.
2000;
24
465-468
-
21
Zimbroff D L, Kane J M, Tamminga C A, Daniel D G, Mack R J, Wozniak P J, Sebree T B, Wallin B A, Kashkin K B. and the Sertindole Study Group .
Controlled, Dose-Response Study of Sertindole and Haloperidol in the Treatment of Schizophrenia.
Am J Psychiatry.
1997;
154
782-791
-
22
Davis J M, Chen N, Glick I D.
A meta-analysis of the efficacy of second-generation antipsychotics.
Arch Gen Psychiatry.
2006;
63
935-937
-
23
Tiihonen J, Walhbeck K, Lönnqvist J, Klaukka T, Ioannidis J PA, Volavka J, Haukka J.
Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
BMJ.
2006;
333
324-327
-
24
Möller H-J.
Antipsychotic agents. Gradually improving treatment from the traditional oral neuroleptics to the first atypical depot.
Eur psychiatr.
2005;
20
379-385
-
25
Adams C E, Fenton M KP.
Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.
Br J Psychiatry.
2001;
179
290-299
-
26
Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J.
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
BMC Psychiatry.
2006;
6
8
http://www.biomedcentral.com/1471-244X/6/8
-
27
Jones P B, Barnes T RE, Davies L, Dunn G, Lloyd H, Hayhurst K P, Murray R M, Markwick A, Lewis S W.
Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Arch Gen Psychiatry.
2006;
63
1079-1087
-
28
Lewis S W, Barnes T RE, Davies L, Murray R M, Dunn G, Hayhurst K P, Markwick A, Lloyd H, Jones P B.
Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia.
Schizophrenia Bulletin.
2006;
32 (4)
715-723
-
29
Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B.
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
Am J Psychiatry.
2001;
158
518-526
-
30
Turner M S, Stewart D W.
Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
J Psychopharmacology.
2006;
20, Supplement
20-37
-
31
Leucht S, Barnes T RE, Kissling W, Engel R R, Correll C, Kane J M.
Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials.
Am J Psychiatry.
2003;
160
1209-1222
-
32
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S.
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics.
Am J Psychiatry.
2006;
163
185-194
-
33
Lexchin J, Bero L A, Djulbegovic B, Clark O.
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
BMJ.
2003;
326
1167-1170
-
34
Gardner D M, Baldessarini R J, Waraich P.
Modern antipsychotic drugs: a critical overview.
CMAJ.
2005;
172
1703-1711
Prof. Dr. med. Jürgen Fritze
Asternweg 65
50259 Pulheim
Email: juergen.fritze@dgn.de
